Pavey Gabriel J, Qureshi Ammar T, Tomasino Allison M, Honnold Cary L, Bishop Danett K, Agarwal Shailesh, Loder Shawn, Levi Benjamin, Pacifici Maurizio, Iwamoto Masahiro, Potter Benjamin K, Davis Thomas A, Forsberg Jonathan A
Regenerative Medicine Department, Naval Medical Research Center, Silver Spring, MD, United States; USU-Walter Reed Surgery, Walter Reed National Military Medical Center, Bethesda, MD, United States.
Regenerative Medicine Department, Naval Medical Research Center, Silver Spring, MD, United States.
Bone. 2016 Sep;90:159-67. doi: 10.1016/j.bone.2016.06.014. Epub 2016 Jun 28.
Heterotopic ossification (HO) involves formation of endochondral bone at non-skeletal sites, is prevalent in severely wounded service members, and causes significant complications and delayed rehabilitation. As common prophylactic treatments such as anti-inflammatory drugs and irradiation cannot be used after multi-system combat trauma, there is an urgent need for new remedies. Previously, we showed that the retinoic acid receptor γ agonist Palovarotene inhibited subcutaneous and intramuscular HO in mice, but those models do not mimic complex combat injury. Thus, we tested Palovarotene in our validated rat trauma-induced HO model that involves blast-related limb injury, femoral fracture, quadriceps crush injury, amputation and infection with methicillin-resistant Staphylococcus aureus from combat wound infections. Palovarotene was given orally for 14days at 1mg/kg/day starting on post-operative day (POD) 1 or POD-5, and HO amount, wound dehiscence and related processes were monitored for up to 84days post injury. Compared to vehicle-control animals, Palovarotene significantly decreased HO by 50 to 60% regardless of when the treatment started and if infection was present. Histological analyses showed that Palovarotene reduced ectopic chondrogenesis, osteogenesis and angiogenesis forming at the injury site over time, while fibrotic tissue was often present in place of ectopic bone. Custom gene array data verified that while expression of key chondrogenic and osteogenic genes was decreased within soft tissues of residual limb in Palovarotene-treated rats, expression of cartilage catabolic genes was increased, including matrix metalloproteinase-9. Importantly, Palovarotene seemed to exert moderate inhibitory effects on wound healing, raising potential safety concerns related to dosing and timing. Our data show for the first time that Palovarotene significantly inhibits HO triggered by blast injury and associated complications, strongly indicating that it may prevent HO in patients at high risk such as those sustaining combat injuries and other forms of blast trauma.
异位骨化(HO)是指在非骨骼部位形成软骨内骨,在重伤员中很常见,并会导致严重并发症和康复延迟。由于多系统战斗创伤后不能使用如抗炎药物和放射治疗等常规预防性治疗方法,因此迫切需要新的治疗方法。此前,我们发现视黄酸受体γ激动剂帕罗西汀可抑制小鼠皮下和肌肉内的异位骨化,但这些模型无法模拟复杂的战斗损伤。因此,我们在经过验证的大鼠创伤诱导异位骨化模型中测试了帕罗西汀,该模型涉及爆炸相关的肢体损伤、股骨骨折、股四头肌挤压伤、截肢以及因战斗伤口感染耐甲氧西林金黄色葡萄球菌。从术后第1天(POD)或POD - 5开始,帕罗西汀以1mg/kg/天的剂量口服给药14天,并在受伤后长达84天内监测异位骨化量、伤口裂开及相关过程。与赋形剂对照动物相比,无论治疗何时开始以及是否存在感染,帕罗西汀均能使异位骨化显著减少50%至60%。组织学分析表明,随着时间的推移,帕罗西汀减少了损伤部位异位软骨形成、骨形成和血管生成,而异位骨常被纤维组织取代。定制基因阵列数据证实,在帕罗西汀治疗的大鼠残肢软组织中,关键软骨生成和成骨基因的表达降低,而软骨分解代谢基因的表达增加,包括基质金属蛋白酶 - 9。重要的是,帕罗西汀似乎对伤口愈合有中度抑制作用,这引发了与给药剂量和时间相关的潜在安全问题。我们的数据首次表明,帕罗西汀能显著抑制爆炸伤引发的异位骨化及相关并发症,有力地表明它可能预防高危患者如遭受战斗损伤和其他形式爆炸创伤患者的异位骨化。